Skip to Content Skip to Search
scientist microscope

About us

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Every day, we help improve the health of millions of people around the world.

Our goal is to become one of the world’s most innovative, best performing and trusted healthcare companies.

What we do

We have a significant global presence with commercial operations in more than 150 countries, a network of 89 manufacturing sites, and large R&D centres in the UK, USA, Belgium and China. 

In Nigeria, our commercial office is located in Ilupeju, Lagos.

Consumer Healthcare

Pharmaceuticals and Vaccines

Scientist handling test tubes in a lab

How we do it

Everyone at GSK is focused on our 3 long-term priorities – Innovation, Performance, Trust, all powered by our performance-focused culture.


Innovation is at the heart of delivering GSK’s purpose, by using our science to develop better medicines, vaccines, and consumer healthcare products. We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

  • £4.6bn

    adjusted R&D investment in 2020

  • 40

    new medicines in development at FY 2020

  • 17

    new vaccines in development at FY 2020


We deliver growth by investing effectively in our business, developing our people and executing competitively.

  • £34bn

    turnover in 2020

  • £9bn

    adjusted operating profit in 2020

  • £5.4bn

    free cash flow in 2020

  • £4bn

    dividends paid in 2020


We are a responsible company – using our science and technology to address health needs, we are focused on making our products affordable and available and being a modern employer.

  • 84%

    employee engagement score on our latest employee survey

  • £250m

    donated in 2020 to community health programmes

  • 1st

    in Access to Medicines Index since the assessment began in 2008